Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Novartis, Otsuka

Drug class:

Ionizing radiation emitter, PSMA inhibitor

Related drugs:

‹

177 Lu-FC705 (0)

BAY 2315497 (0)

177Lu-satetraxetan-lilotomab (4)

ibritumomab tiuxetan (3)

Actinium-225 conjugated to daratumumab (2)

lutetium Lu 177 dotatate (2)

radium Ra-223 dichloride (2)

177Lu-DTPA-omburtamab (0)

177Lu-LNC1003 (0)

177Lu-LNC1004 (0)

177Lu-LNC1010 (0)

177Lu-P17-087 (0)

177Lu-P17-088 (0)

177Lu-PSMA-R2 (0)

iodine I 131 tositumomab (0)

samarium-153 DOTMP (0)

epratuzumab Y-90 (0)

lutetium-177 DOTA satoreotide (0)

67Cu MeCOSar octreotate (0)

177Lu-edotreotide (0)

JNJ-63898081 (1)

177 Lu-FC705 (0)

BAY 2315497 (0)

›

FOLH1 positive	Prostate Cancer	FOLH1 positive	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1	lutetium Lu 177 vipivotide tetraxetan Sensitive: A1 - Approval lutetium Lu 177 vipivotide tetraxetan Sensitive : A1
No biomarker	Prostate Cancer	No biomarker	Prostate Cancer	lutetium Lu 177 vipivotide tetraxetan Sensitive: B - Late Trials lutetium Lu 177 vipivotide tetraxetan Sensitive : B	lutetium Lu 177 vipivotide tetraxetan Sensitive: B - Late Trials lutetium Lu 177 vipivotide tetraxetan Sensitive : B
FOLH1 expression	Prostate Cancer	FOLH1 expression	Prostate Cancer	pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive: C3 – Early Trials pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive : C3	pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive: C3 – Early Trials pembrolizumab + lutetium Lu 177 vipivotide tetraxetan Sensitive : C3
ATM mutation	Prostate Cancer	ATM mutation	Prostate Cancer	enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan Sensitive: C4 – Case Studies enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan Sensitive : C4	enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan Sensitive: C4 – Case Studies enzalutamide capsule + lutetium Lu 177 vipivotide tetraxetan Sensitive : C4